GU ASCO 2024 Highlights with Dr. Tian Zhang – CONTACT-02, BRCAAway, AMBASSADOR, Keynote-564

from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers

In discussion with Dr. Tian Zhang, covering the Genitourinary ASCO 2024 meeting highlights from the Community Oncology perspective. We covered 4 important practice informing studies from GU ASCO with Dr. Zhang: - CONTACT-02: Phase 3 study of cabozantinib plus atezolizumab vs second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer - BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer bearing homologous recombination-repair mutations - AMBASSADOR: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma vs observation - Keynote-564: Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma

What this episode covers

NOW PLAYING

0:00 17:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Brothers: Practice-Changing Cancer Discussions?

This episode is 17 minutes long.

When was this Oncology Brothers: Practice-Changing Cancer Discussions episode published?

This episode was published on February 8, 2024.

What is this episode about?

Can I download this Oncology Brothers: Practice-Changing Cancer Discussions episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.

URL copied to clipboard!